Details

Autor(en) / Beteiligte

• Szerman, Nestor
• Basurte-Villamor, Ignacio
• Vega, Pablo
• Martinez-Raga, Jose
• Parro-Torres, Carlos
• Cambra Almerge, Julia
• Grau-López, Lara
• De Matteis, Mario
• Arias, Francisco

Titel

Correction to: Once‑Monthly Long‑Acting Injectable Aripiprazole for the Treatment of Patients with Schizophrenia and Co‑occurring Substance Use Disorders: A Multicentre, Observational Study

Ist Teil von

• Drugs -- real world outcomes, 2020-03, Vol.7 (1), p.85-85

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2020

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• A randomized, 1-year follow-up study comparing LAI aripiprazole with LAI paliperidone in patients with psychosis, mostly schizophrenia, and SUD reported a large effect of the change from baseline in the CGI severity score, from 5.9 to 2.4 for LAI aripiprazole and from 5.7 to 2.6 for LAI risperidone [29].